Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
Beijing, CN
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.70% | -5.95% | -30.00% | -20.71% | -38.52% | -23.08% | -15.52% | -19.67% | -78.08% | -66.02% | -66.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-66.5% Q4'25: -66.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+10.0% Q4'25: +56.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-438.9% Q4'25: -729.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-317.8% Q4'25: -1,322.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +206.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.15× Q4'25: -0.45× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
486.29M
est: 464.35M (+4.7%)
|
152.81M
est: 328.92M (-53.5%)
|
95.75M
est: 115.47M (-17.1%)
|
63.52M
est: 21.57M (+194.5%)
|
155.71M
est: 199.93M (-22.1%)
|
52.14M
est: 114.15M (-54.3%)
|
750.41M
689.74M – 811.07M
+557.4% YoY
|
278.03M
35.40M – 520.66M
-62.9% YoY
|
329.08M
232.03M – 426.13M
+18.4% YoY
|
| EBITDA |
-1.50B
est: -464.35M (-224.0%)
|
-289.83M
est: -328.92M (+11.9%)
|
-355.80M
est: -115.47M (-208.1%)
|
-325.73M
est: -21.57M (-1,410.3%)
|
-192.36M
est: -199.93M (+3.8%)
|
-143.46M
est: -114.15M (-25.7%)
|
-750.41M
-811.07M – -689.74M
-557.4% YoY
|
-278.03M
-520.66M – -35.40M
+62.9% YoY
|
-329.08M
-426.13M – -232.03M
-18.4% YoY
|
| EBIT |
-1.51B
est: -464.35M (-225.8%)
|
-300.62M
est: -328.92M (+8.6%)
|
-369.59M
est: -115.47M (-220.1%)
|
-350.81M
est: -21.57M (-1,526.6%)
|
-203.19M
est: -199.93M (-1.6%)
|
-165.68M
est: -114.15M (-45.1%)
|
-750.41M
-811.07M – -689.74M
-557.4% YoY
|
-278.03M
-520.66M – -35.40M
+62.9% YoY
|
-329.08M
-426.13M – -232.03M
-18.4% YoY
|
| Net Income |
-1.51B
est: -1.52B (+0.3%)
|
-301.19M
est: -341.43M (+11.8%)
|
-371.86M
est: -331.18M (-12.3%)
|
-359.12M
|
-155.71M
est: -123.88M (-25.7%)
|
-142.20M
est: -69.68M (-104.1%)
|
429.77M
361.49M – 498.04M
+716.8% YoY
|
-44.18M
-257.05M – 168.69M
-110.3% YoY
|
-76.31M
-105.57M – -47.06M
-72.7% YoY
|
| SGA |
53.84M
est: 155.64M (-65.4%)
|
16.88M
est: 110.25M (-84.7%)
|
42.55M
est: 38.70M (+9.9%)
|
46.62M
est: 9.19M (+407.0%)
|
43.05M
est: 85.24M (-49.5%)
|
29.54M
est: 48.67M (-39.3%)
|
319.94M
294.07M – 345.80M
+557.4% YoY
|
118.54M
15.09M – 221.98M
-62.9% YoY
|
140.30M
98.93M – 181.68M
+18.4% YoY
|
| EPS |
-3.97
est: -1.96 (-102.5%)
|
-0.40
est: -0.44 (+9.2%)
|
-0.49
est: -0.43 (-14.6%)
|
-0.46
|
-0.20
est: -0.16 (-25.0%)
|
-0.18
est: -0.09 (-100.1%)
|
0.55
0.47 – 0.64
+716.8% YoY
|
-0.06
-0.33 – 0.22
-110.3% YoY
|
-0.10
-0.14 – -0.06
-72.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.16% | 103.7K | 0.59% |
| 2 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 19.1K | 0.74% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 161.1K | 0.65% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 67.7K | 0.72% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 43.0K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 71.3K | 0.55% |
| 7 | State Street SPDR S&P China ETF GXC | 0.01% | 46.5K | 0.59% |
| 8 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 726.4K | 0.07% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 22.4K | 0.18% |
| 10 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 546.7K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yinxiang Wang | Founder, Co-CEO & Executive Chairman | 4M | — |
| Yunyan Hu | Executive Vice President & Executive Director | 3M | female |
| Xiaojie Wang | Executive Director & President of Administration | 3M | female |
| Qing Xue | Joint Company Secretary | — | female |
| Tao Yang | Vice President of Human Resources | — | female |
| Andrea Wang-Gillam | Co-CEO, Executive VP, Chief Medical Officer and Global Head of R&D | — | — |
| Yanping Wang | Executive Vice President of Non-Clinical R&D | — | female |
| Ming Fai Chung | Joint Company Secretary | — | male |
| Yuli Ding | Executive Vice President of Clinical Development | — | female |
| Haijun Wang | Senior Vice President of Information & Data Management | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1167.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
